MSB

3.21%

$1.13 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-143

First 143 Last

Share
Profile

Follow
col69

15,643 Posts.

5711

26/03/24

14:58

Post #: 73065527
Share

Originally posted by JB1975 ↑

And relative to the second BLA what more did they have to consider that they didn't have before?

Well, presumably the handful of survivers at four years (last report) are still alive and more time has passed. And presumably the sympathetic supporters Levine, Ferrara etc are still hooked into an extensive network of MAGIC data collecting -so they'd still be offering "real world" data by way of comparison. And that would still be good. The same arguments (emotional not scientific) that got votes at ODAC would still be appealing to the same folk that don't understand the science and the stats. But that's most people. Its just not usually the FDA.

I wouldn't expect survivers to cease being survivors because their immune systems I'd expect to have been essentially reset - successfully. So I'd expect they'd keep on surviving.

But none of that changes that there were only a handful maybe eleven or so patients that got a known tightly controlled dosing of the product without confounding variables - so it still has to be the case that the product that went into the patients that did show very good longevity wasn't sufficiently characterised in a statistically large enough number - I think.

Still think more data needed with new trial in adults.

If I had to bet at this point I'd bet a repeat of history - SI cranking up the rhetoric and getting ready for another go at trying to sympathy claim an outcome where the science and stats don't justify that outcome. CRL number 3 coming up most likely in my opinion.

To be fair opinions aren't worth much without evidence and chains of reasoning behind them. Even a few errors in the drafting of the announcement changes things. I don't think the board or Silviu would lie or deliberately open themselves up to legal risk - but I can't see how they cannot be either mistaken or that the FDA has made a mistake (no amount of retrospective back-filling or data mining can make any difference to what went into the handful of patients in the GVHD trial being something and not other things at a certain point in time) if the MSB board has accurately reflected the true substance of what the FDA has said to the MSB company officers.

Expand

Here we go again .... everybody has made a mistake except you JB ?

Don't you think the delay in removing the 'pause' might have involved some legal eyes looking over the wording contained in said announcement after (I don't know) a perusal of the FDA documentation by our legal representation ? It's funny to see an anonymous poster on HC claim yet again that Mesoblast has made a mistake when he/she hasn't even seen the FDA minutes of the meeting / advice ? You seriously can't make this stuff up

Don't be afraid to trade some (IMO of course) .... entirely up to you but I thought 50.5 cents was ok to ditch some - it may retreat / it may not ? GLTAH

MSB Price at posting: 49.8¢ Sentiment: Buy Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

There are more pages in this discussion • 954 more messages in this thread...

First 143 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-143

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-143

Top Stories

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACCC seeks Olam divestments before it can buy Namoi Cotton

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News